504673664 12/06/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4720386

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ACTION MEDICINES, S.L.	11/15/2011

RECEIVING PARTY DATA

Name:	AMDERMA PHARMACEUTICALS, LLC
Street Address:	995 ROUTE 202/206
City:	BRIDGEWATER
State/Country:	NEW JERSEY
Postal Code:	08807

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15455844

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: | murphy@dsiplaw.com Correspondent Name: SERVILLA WHITNEY LLC Address Line 1: 33 WOOD AVENUE SOUTH

Address Line 2: SUITE 830

Address Line 4: ISELIN, NEW JERSEY 08830

ATTORNEY DOCKET NUMBER:	AMD0003-04CT
NAME OF SUBMITTER:	DONNA R. FUGIT
SIGNATURE:	/Donna R. Fugit, Reg. #32135/
DATE SIGNED:	12/06/2017

Total Attachments: 11

source=00706757#page1.tif

source=00706757#page2.tif

source=00706757#page3.tif

source=00706757#page4.tif

source=00706757#page5.tif

source=00706757#page6.tif

PATENT REEL: 044313 FRAME: 0539

504673664

source=00706757#page7.tif
source=00706757#page8.tif
source=00706757#page9.tif
source=00706757#page10.tif
source=00706757#page11.tif

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), dated as of November, 2011, is made and entered into by and between Action Medicines, S.L., a company organized under the laws of Spain ("Assignor"), and AmDerma Pharmaceuticals, LLC, a Delaware limited liability company ("Assignee"). Unless otherwise defined herein, all capitalized terms used in this Assignment shall have the meanings set forth in that certain Purchase Agreement, dated as of November, 2011 (the "Purchase Agreement"), by and among Assignor, DermAct Pharmaceutical, Inc., a Delaware corporation ("DermAct") and Assignee.

WHEREAS, concurrently with the execution and delivery of this Assignment, Assignor, DermAct and Assignee are consummating the transactions contemplated by the Purchase Agreement.

NOW, THEREFORE, for good and valuable consideration as listed in detail in Section 4 of the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

- Assignment. In accordance with and subject to the terms and conditions of the Purchase Agreement, Assignor does hereby acknowledge that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto Assignee, its successors, legal representatives, and assigns, Assignor's entire right, title, and interest throughout the world in, to, and under the patents and patent applications listed in Exhibit A attached hereto (the "Patents and Patent Applications"), including without limitation all patents and patent applications claiming priority to and/or benefit of the Patents and Patent Applications including but not limited to divisions, continuations, and continuations-in-part thereof and all reissues, reexaminations, and extensions thereof, and all priority rights under the International Convention for the Protection of Industrial Property for every member country, and all applications for patents (including without limitation related rights such as utility-model registrations, registrations, inventor's certificates, and the like) heretofore or hereafter filed in any country/countries foreign to the United States, and all patents (including all extensions, renewals and reissues thereof) granted for in any country/countries foreign to the United States. In addition, Assignor does hereby sell, assign, transfer and convey to Assignee, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to Assignee, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said patents and patent applications before or after issuance. Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks, and any officials of countries foreign to the United States whose duty is to issue patents on applications as aforesaid, to issue all Letters Patents resulting from the Patents and Patent Applications in the name of Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.
- 2. <u>Further Assurances</u>. AM further agrees that it will at any time and from time to time, at the request of AmDerma, execute and deliver to AmDerma all other and further instruments reasonably necessary to vest in AmDerma the right, title and interest in the Patent which this instrument purports to transfer to AmDerma.

PATENT

REEL: 044313 FRAME: 0541

- Limitation. Notwithstanding anything to the contrary contained herein, the Assignee does not hereby assume or agree to perform or pay any liabilities or obligations of either Assignor that are not Assumed Liabilities.
- Amendments. This Assignment may only be amended by a writing signed by each Assignor and Assignee.
- Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute a single document.
- Delivery Pursuant to Purchase Agreement. Notwithstanding anything to the contrary herein, Assignor and Assignee is executing and delivering this Assignment in accordance with and subject to all of the terms and provisions of the Purchase Agreement. To the extent of any conflict between the terms and conditions of this Assignment and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall govern, supersede and prevail.
- Binding Effect. This Assignment shall be binding upon, and shall inure to the benefit of, Assignors and Assignee and their respective successors and assigns.
- Governing Law. This Assignment shall be governed by and construed in accordance with the laws of the State of New Jersey, without regard for conflicts of laws principles.

[SIGNATURE PAGE FOLLOWS]

REEL: 044313 FRAME: 0542

IN WITNESS WHEREOF, this Assignment	has been duly executed and delivered by the
parties hereto as of the date first above written.	And the second of the second o
discovered and exercising a source of self-with	OUTS OF EMPARITHMENT ASSESSED.
or earny of the third of the AMMAN	ASSIGNOR: OF CONTRACT OF CONTR
the reservoirs of the first sections.	
earling collaboration to the first and the	/ las
. we to sign in the decreasing a given	
Market Committee of the Control of t	~ 10000 ~ 1000
	Name: Santiago de Gracia
	Title: CEO-Consejero Delegado
	er en
	Sign in presence of a Notary and have Notary attach Acknowledgement
•	ASSIGNEE:
	AMDERMA PHARMACEUTICALS, LLC
	AMDERMA PHARMACEUTICALS, LLC
	By: Name: Chirag Patel
	Title: Manager and Prosidet
	Sign in presence of a Notary and have Notary attach Acknowledgement
	Attorney at Law 1 State of NJ Anshu Pathak, ssq.
	Anshu Pathak, ssg.

../... T I M A C I O N: -----

YO, MIGUEL KRAUEL ALONSO, Notario de Málaga, Ilustre Colegio de Andalucía . ------

VISTA Y LEGITIMADA: Doy fe que la firma y rúbrica que precede de DON SANTIAGO DE GRACIA CLEMENT con D.N.I./N.I.F. número 00100848-Q, la considero legitima por haber sido puesta a mi presencia y haberle identificado por su reseñado documento, que me exhibe y le devuelvo.-

En Málaga, a veintitrés de septiembre de dos mil once .

APLICACION ARANCEL LEY DE TASAS HONORARIOS: 6,16 €

LIBRO INDICADOR: Hoja N° 260 Section 2ª

THE PRINCIPAL OF THE PR

EXHIBIT A

TÖ

PATENT ASSIGNMENT

(See Attached)

PATENT

REEL: 044313 FRAME: 0545

Ref	F - 0 - 7.3	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Tyler to the late wi		rate and a	B 1 9 - 25 95 1.6	5
No.	Title of Invention	7 7		Appln No.	Filed		الأراب المرابع
170.	THE OLDIVERNOR.	Country	Status	Appurau.	8/2/2006	Patent No.	Issued
	Use of Dihydroxy-	3834.2	医马勒氏性		PCT Filing	1. Takabi (983. 43	
1	benzenesulfonic acids.		Response to		Date		阿尔克克克
4.7	in the Production of	was in gold.	non-final GA		2/16/2005	Late Bank C	
4 4 5	Medicaments for		ried		Priority		
18 7 8	Angiopenic Diseases	医髓色素	6/30/2010	P. 图 美國政	2/16/2005	US20080293816	M X Marin
1.1	such as Cancer and	[1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	awaiting to	10 mm (12 h)	(PCT Eiline)	Pub date	
202	Psonasis	US	PTO action	10/588,166	2/17/2004	11/27/2008	
71	Use of Diliyotoxy-	Maragian N		(1) 建氯甲基酚类	1.0	A sec Massers	19 10 14 1
	benzenesultonic acids	\$ \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\					19 34 Kar
876	in the Production of	le.		Market S	70000000000000000000000000000000000000		清,至独物。
P2280	Medicaments for						
3BER	Anglogenesis-	le iibii	Granted	EP05708114		以下,19 17年19月1日	* 1 B
P	dependent Diseases	'Belgium	Validated	* (* 13	16/02/2005	EP1719509	भविति प्र
	Use of Dihydroxy-		erit Gran Silvan			化成本化化物	užio stri
13.410%	benzenesulionic acads			hi shiringil			
Danes.	in the Production of	ha Masi	1 - 3 - 1 - 3 \ 1 - 3 \ 1 - 3 \ 1 - 3 \ 1 - 3 \ 1 \ 1 \ 1 \ 1 \ 1 \ 1 \ 1 \ 1 \ 1 \	图 金属镇			
P2280	Medicaments for	h dayah darin.		Pontono III			
P	Angiogenesis- dependent Diseases	Germany	Granted Validated	EP05708114	16/02/2005	EP1719509	
F. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10	Use of Dihydroxy-	- Cermany	- Vanualeu	Andreas (Sec. 1997)	. 10/02/2000	Era Hesue	ref 1875 to 12
1 19.10	benzenesulfonic acids			等有效轉換器		1725 N. 1025 S. 202 (N. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	
111.2	in the Production of			41 94 TER NE		民人的意思。例	以及其类
P2280	Medicaments for	大多 變元			计数工图 数	E01719509	19年的海绵和1964 1988年 - 英国安全部
1DKE	Angiogenesis		Granted	EP05708114		DKIEP 1719509	
P	dependent Diseases	Denmark	Validated		16/02/2005		新世界的教 验
4 3 3	Use of Dihydroxy-	(3.5 gr 17.0)	1.12134.747377.3	ราย (ค.ศ. 25 กระการ ค.ศ. 27 กระการ	314 34 1 20 0	North Art Art Control	raulia, viiji
	benzenesulfonia acids	l iv	lon inis s				
1.13	in the Production of	130 3					$\mathcal{H}_{\mathcal{A}}$
P2280	Medicaments for		14 4 14 3 1	a di santa di mata di mana di santa di san			. 일 (1월 : 36 원년 13년 왕 (6) 전 (8)
3ES0	Angiogenesis			P200400371			
0	dependent Diseases	Spein	Granned (1)	5 5 7 4	17/02/2004	ES2238924AB	OUESCAR VISAAA
1	Use of Dirvinory- benzenesulfonic acids	10	PW 对领域	[설립함 20] 20			
	in the Production of						
P2280	Medicaments for		医热膜夹片			医型器肾髓 癌	
3ESE	Angiogenesis	Party 18	Granted	EP05708114	E 医对极电影	EP1719509	
P	dependent Diseases	Spain	Validated	13	16/02/2005	ES233444713	2世 軍隊
	Use of Dihydroxy-			10.00	10	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	337 374
1 1/4	benzenesulfonie acids			i nelok	La Harris		
1 79	in the Production of	10 11 11		12 K NEW	TAMES CANAL	[27] [7] [7] [7] [7] [8]	
P2280	Medicaments for		医安息 背景 建氯基		IN THE	医甲烷医酚糖	
3FRE	Angiogenesis		Granted	EP05708114	Kara Mak	操作的可能的控制	The state of the
P	dependent Diseases	Irrance	Validated		16/02/2005	EP1719509	77 (1, 2, 1, 1)
1	Use of Dihydroxy-	[\		ta in the second	[,) 文学		Obstacles
J	benzenesulfonic acids	1 6 A		柯 松龙	MT		
16	in the Production of		B 25 15	丰道 气压器	147年美		
P2280	Medicaments for	I de la	The second of	maznanı			
3GBE		United Kingdom	Granted Validated	EP05708114	16/02/2005	EP1719509	1.5
P2280	Use of Dihydroxy-	azingden)	vandated A	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	10/02/2005)	EL1.10.9909	
			1 Francisco	EP05708114	6. dark 40	100	
THE PARTY	i héhyéngelültnété aglac						
FIEE.	benzenesülfonie acids in the Production of	Aleeland	Granted / Validated /	4 1/3 °	16/02/2005	EBP1719509	

A774132456.

	Medicaments for Anguingenesis dependent Diseases						
P2280	Use of Dihydroxy- bonzenesulfunic solds in the Production of Medicaments for Angiogeocsis		Granted	EP05708114		ERI719509	
P "	dependent Diseases	Italy	Validated	å kravi r y giveta å	16/02/2005	47515BE2010	
P2280 3NEE P	Use of Dihydroxy- benzenesulfunic acids in the Production of Medicantents for Angiogenesis: dependent Dissasss	Notherlan	Granted Velidated	EP057081-14	16/02/2005	PP1719509	
P2280 31/TE P	Use of Ditydroxy- bertzenssulfonts acids in the Production of Medicarrients for Angiogenesis dependent Diseases	Portugal	Orantod Validuted	EP057081/4		EP1719509	
P2803 SEEP	Use of Dihydroty- benizenesulfamic acids in the Production of Medicariems for Angrogenesis dependent Diseases	∦Sweden	Granted Validated	EP05708114:	16/07/2005	EP1719509	
PZ803 AUP C	Use of Dillydroxy- benzenesulfonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Ausmlia		2005211956	16/02/2005		
• P2803 CAP C	Use of Diffydroxy: benzenesufcont acids in the Production of Medicaments for Angrogenesis dependent Diseases	Canada		2.555.246	16/02/2005		
P2803: CNP.	Use of Dihydroxy- benzenesia fonic scids in the Production of Medicaments for Approperests dependent Diseases	China		2005800051 87.3	16/02/2005	ĆN∜101014330X	
P2803	Use of Dibydroxy- benzenesultonic acids in the Production of Medicaments for Angiogenesis- dependent Diseases	Îsrael		17/7238	16/02/2005	All and the second seco	
#2803 #PPC	Use of Dihydroxy- benzenesulfanie acids in the Production of Medicaments for	Januar Japan		2006- 553602	706/02/2005	gelich feneganis f	

A7741524563

A	Angiogenesis-						
	Use of Dinydroxy- benzenesulfonic acids						
P2803	in the Production of Medicaments for						
MXP C	Arigiogenesis- dependent Discuses	Мехісо	Cirented	PAIA120061 009295	16/02/2005	269609	
	Use of Dinydroxy- benzenesultonic acids in the Production of						
P2803 UAP	Medicaments for Angiogenesis			2006			
C	dependent Diseases	Ukraine	Granted	09127FM	16/02/2005 8/16/2006	36399	
1-10		Way			CIP-of (0/528,166		
			Response to		above, filed 8/2/2006		
	Methods of use for 2,5-dinyaroxybenzeno		final Office Action and	TO THE SECOND	(Nati Phase Filing)		
	sulfornic stoid compounds for the		RCE filed. 12/28/2009		2/18/2005 (PCT		
202.2	Treatment of Cancer, Rosacea and Psoriasis	us	>awaiting PTO action	11/506,469	Files). 2/17/2004	US20070149618 Pub.date 6/28/2007	The P
					8/15/2007 8/16/2006		
					and CIP-of 11/506,469a		
					bove, filed 18/16/2006		
			Notice of		which is CIP of		
739 735 735			Appeal filed 4753/2010		10/588,166 above filed		
	Lise of Dihydroxy		Response to final OA mid RCE fine		E/2/2006(Na t Phase Filing)		
1 136g	benzenesulfonic derivatives for		10/15/2010 (6/7) FINAL		2/16/2005 (PCT		
202	Treating Actinic Keratosis	in the second	deadline 41/15/2010 7/7)	11/839.508	Filing), 2/17/2004	USZ0080125485 Pub.date 5/29/2008	
1 8	and to be a pro-	1.3	1 4 W	AL AND	Divisional	Basic Salah	
					11/506,469, above filed		
					18/16/2006 white a		
	Methods of use for				CIP of 10/588.166.		
	2,5-dihydroxybenzene sulfonic acid				above filed -8/2/2006(Na		
Table 1	Compounds for the Treatment of Cancer,		Pending . awalting PTO		t. Phase	US200901)1779	第一次
202,3	Rosacca and Psoriesis	Li KRUS TA	ROTION	12/257,854	2/16/2005	Pub.date 4/30/2009	124 15 2 5

KIT4152456:1

42	
Lade of the court of the court	Y TANKA TO THE TANK OF PCT Piling IN THE YOUR AND THE RES
	Date:
	A CONTROL OF THE STATE OF THE S
Use of Ditydroxy	
berizenesulionie	
derivatives for	
P3195 Treating Actinic	H 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
EPPC Keratosis BU	ALE TO \$15 YOU THE PURE OF THE RASIZED THE THEP20540 SECTION ASSESSED.

A/74 (32454,)

		 				F*	
Ref.	Title of Invention	Соинту	Status	Apoln No.	Filed	Patent No.	lasued
11.	Albert Med	305 (3 (38)	Final CA	vány výc	-vir \ it.	V. 12. 1834 J.A.	5304,44
		提出時期	maried 7/1/2010				
		Maria M	Response to		193. Lai	医自身拉维	18
100			final OA		30.14.88	1-11	
()	Use of Dihydroxy- benzenesulfonic	1.5	10/1/2010 (3/6) Final			14.14年新	Said (
	derivatives for		dendime			US20080114075	
1.44	Treating		1/1/2017	11/839,51		Pub desc	# 33W
203	Dermatitis Use of Dinydroxy	US	(6/6)	7 - AN 2 7 - AN4 CARLON TOTAL	7/2/2007	5/15/2008	138d 25 1
Land to	benzenesulionic	V V			的為其外		以类型数
P319	derivatives for		EUSELE				
6EP PC	Treating Demonitis	EU	i effect	EP077884 26.0	8/15/2007	EP2056815	自動物
\$ 10 m	This payer was	7	Final OA		三十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二	and the state of the state of	e Harahya
7			mailed 5/5/2010	是数数数数			
111		4 1 3V	Response to				
1	Use of 2.3-	44)	anal OA and	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	I LA		
	dihydroxybenzene		10/5/2010	自由物類	(本) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1		
	compounds and		(5#6) Feesil				
	Derivatives for the Treatment of		deadine 11/5/2010	11/839,51	8/16/2006 ; 17/2/2007	US20080113947/ Pultidate	
204	Rosacea	US	16/6)	5		5/15/2008	
	Use of Danydroxy-	/ y. 18					2. 計劃
P319	derivatives for the	等。如此			第二次版		
SEP .	Treatment of	eu		EP077884			1.5
₽C `	Rosaced	13 3 3 1 2	Final DA	28.6	8/15/2007	EP2056813	
	Transference (1.)		mailed	[3 45 10 10 10 10 10 10 10 10 10 10 10 10 10	之間 一个一种	医复数形式	第123 4
16 A. 15			5/21/2016 Response to				
			final OA and				5: #8456.291 5:20:0204
į	Use of 2,5- dinydroxybenzene		RCE -10/21/2010				
100	compounds and		(5/6) Fruil	建物的		Min To The	3450 (F)
0.00	Derivatives for the		dedine			U620080113948	
205	Treatment of Psoriasis		11721/2010 (6/6)	14/839,52	8/16/2006 7/2/2007	Pub date 5/15/2008	1000 E
	Use of Dihydroxy-	N 17 1	la calla hi	Line		ACA III de se	M. M. S. V.
P319	benzenesultonic i	内膜板				類數學學	
9EP	Treatment of			EP077884		[] / () / () / () / () / () / () / ()	
PC .	Psomasis Use of 2.5-	EU		29.4	8/15/2007	EP2056814	1.
	dinydroxybenzene	111	Response			Maria Maria	
	compounds and		filed			The second secon	
ىد. ئادىقى ئىد	Derivatives for the Treatment of Skin.	15. 1	7/26/2010 Tewaiting PTO.	11/830.59	871672006	US20080114060 Pub date	h il in il
206		in sus 🏥	action	12 × 1	7/2/2007.	5/15/2008	

A/74152#56:E

		Filing date	
		27(7/2009 Priority	
		2/15/2008 (US	
Skin Penetration Entirencing	Penking + (National	Provisiona (1)	
2.0 Systems for Polar Drugs	US Stage Engered 8/16/2010)	12/867,87	NA .
		Priority 1/3/2008	
Processes for the Preparation of 2.5	Pending (National	Filing date	
dihydroxynenzene 212 sulfonic Acid Salts	1 US 5 7/2/2010)	12/811/62 1/2/2009	IN MARKET AND THE

M/74152456:1

RECORDED: 12/06/2017 **REEL: 044313 FRAME: 0551**